Cell Based Assay Development Service

Our scientific experts have many years of experience in toxicological and pharmacological cell-based assay development. trenzyme offers the unique advantage that we can handle any cell type (cell lines, iPSC-derived cells, primary cells etc.). Just tell us your requirements (cell type, biological & technical endpoint) and our team will implement a comprehensive protocol, perform the assay in our laboratories and provide you with the desired data.

Learn more
trenzyme Cell-Based Assay Development Service Icon

Cell Based Assay Development Service

Save Valuable Time For Your Research Project

Current drug development and toxicological testing strategies can be costly and often have high failure rates in later stages of development. Accordingly, cell-based assays are important tools for screening new drug candidates before moving on to expensive animal model testing. Our experienced assay experts are dedicated to accelerating your screening capabilities. With our many years of experience in cell-based assay development, you can save valuable time for your research project by outsourcing time-consuming workflows to us.

Pharmaceutical companies use a variety of approaches to drug discovery. Historically, large numbers of compounds have been tested in high-throughput biochemical assays. However, the complexity of disease backgrounds has increased the need for more physiological systems and the use of cell-based assays to predict the response of the organism. trenzyme specialises in cell-based assays using various cell lines and state-of-the-art technologies. Our highly skilled experts are able to develop customized cell-based assays and provide reliable results to help you accelerate your screening capabilities. In addition, together with our stem cell experts, complex predictive and translational in vitro assays can be combined with highly physiological human stem cell-derived cell types to provide advanced compound testing solutions.

Cell Based Assay Development Service

Main Advantages

  • Benefit from a full technology transfer of your assay or let our assay service develop your assays according to your needs.
  • Development of assays based on basic cell lines, customized cell lines or iPSC-derived cell types.
  • Best starting point for your assay development, drug screening and functional studies
  • Broad expertise in assay development for in-vitro-toxicology and pharmaceutical testing.
  • Wide range of techniques to measure endpoints (FACS, Immunostaining, ELISA, Western blot, qPCR).
  • Our custom ➥ cell line development service enables the production of assay cell line and therefore the whole process of cell-based assay development is possible from one-stop.
  • GMP-like documentation available on request.

Process of

Cell Based Assay Development Service

Cell-Based-Assay-Development-Service_Process-Steps

Get a Quote

Contact Us

Your Benefits

From Working With Us

icon transparency & communication

Transparency & Communication

Your project manager keeps you constantly informed on the progress of your project.

icon longstanding expertise

Longstanding Expertise

Since 2000, our highly qualified scientific experts accelerate your innovation.

icon optimized performance

Optimized Performance

trenzyme‘s assay service enable a time-saving workflow for your project.

icon high quality blue

High Quality Standards

As an ISO-certified company, all projects are completed following high standards.

What Our Clients Say About Us

We have expanded and tested the clonal cell lines and we are extremely happy with their performance. Needless to mention, that it was possible because the process of generation of cell lines at trenzyme was very efficient and robust. I would definitely be interested in getting the engineered cell lines from trenzyme in the future, if the need arises.

Dr. Harish Pai Biocon Research Center, Bangalore, India
clients logo biocon trenzyme

Application Note

Assay Services using a standard cell line: HepG2

Download Application Note

Get a Quote

Contact Us

Relevant Publications of trenzyme’s Highly Qualified Scientific Team

Classification of Developmental Toxicants in a Human iPSC Transcriptomics-Based Test. Chemical Research in Toxicology 2022 35 (5), 760-773 (2022)

Cherianidou A, Seidel F, Kappenberg F, Dreser N, Blum J, Waldmann T, Blüthgen N, Meisig J, Madjar K, Henry M, Rotshteyn T, Marchan R, Edlund K, Leist M, Rahnenführer J, Sachinidis A, and Hengstler JG

 

➥Read more

A human stem cell-derived test system for agents modifying neuronal N-methyl-D-aspartate-type glutamate receptor Ca2+-signalling. Arch Toxicol. 2021 May;95(5):1703-1722. (2021)

Klima S, Brüll M, Spreng AS, Suciu I, Falt T, Schwamborn JC, Waldmann T, Karreman C, Leist M

 

➥Read more

Development of a neural rosette formation assay (RoFA) to identify neurodevelopmental toxicants and to characterize their transcriptome disturbances. Arch Toxicol. 2020 Jan;94(1):151-171. doi: 10.1007/s00204-019-02612-5. Epub 2019 Nov 11. PMID: 31712839. (2020)

Dreser N, Madjar K, Holzer AK, Kapitza M, Scholz C, Kranaster P, Gutbier S, Klima S, Kolb D, Dietz C, Trefzer T, Meisig J, van Thriel C, Henry M, Berthold MR, Blüthgen N, Sachinidis A, Rahnenführer J, Hengstler JG, Waldmann T, and Leist M

 

➥Read more

Establishment of a human iPS cell-derived neuronal model cell to study synaptic signaling (2020)

Traub S

 

➥Read more

The EU-ToxRisk method documentation, data processing and chemical testing pipeline for the regulatory use of new approach methods. Arch Toxicol. 2020 Jul;94(7):2435-2461. doi: 10.1007/s00204-020-02802-6. Epub 2020 Jul 6. PMID: 32632539; PMCID: PMC7367925. (2020)

Krebs A, van Vugt-Lussenburg BMA, Waldmann T, Albrecht W, Boei J, Ter Braak B, Brajnik M, Braunbeck T, Brecklinghaus T, Busquet F, Dinnyes A, Dokler J, Dolde X, Exner TE, Fisher C, Fluri D, Forsby A, Hengstler JG, Holzer AK, Janstova Z, Jennings P, Kisitu J, Kobolak J, Kumar M, Limonciel A, Lundqvist J, Mihalik B, Moritz W, Pallocca G, Ulloa APC, Pastor M, Rovida C, Sarkans U, Schimming JP, Schmidt BZ, Stöber R, Strassfeld T, van de Water B, Wilmes A, van der Burg B, Verfaillie CM, von Hellfeld R, Vrieling H, Vrijenhoek NG, and Leist M

 

➥Read more

Examination of microcystin neurotoxicity using central and peripheral human neurons. ALTEX. 2021;38(1):73-81. doi: 10.14573/altex.2003182. Epub 2020 Jun 23. PMID: 32591837. (2020)

Klima S, Suciu I, Hoelting L, Gutbier S, Waldmann T, Dietrich DR, and Leist M

 

➥Read more

Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data. ALTEX. 2019;36(4):682-699. doi: 10.14573/altex.1909271. Erratum in: ALTEX. 2020;37(1):164. PMID: 31658359. (2019)

Krebs A, Waldmann T, Wilks MF, Van Vugt-Lussenburg BMA, Van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, Pallocca G, Luijten M, Leite SB, Kustermann S, Kamp H, Hoeng J, Hewitt P, Herzler M, Hengstler JG, Heinonen T, Hartung T, Hardy B, Gantner F, Fritsche E, Fant K, Ezendam J, Exner T, Dunkern T, Dietrich DR, Coecke S, Busquet F, Braeuning A, Bondarenko O, Bennekou SH, Beilmann M, and Leist M

 

➥Read more

Major changes of cell function and toxicant sensitivity in cultured cells undergoing mild, quasi-natural genetic drift. Arch Toxicol. 2018 Dec;92(12):3487-3503. doi: 10.1007/s00204-018-2326-5. Epub 2018 Oct 8. Erratum in: Arch Toxicol. 2019 Jun;93(6):1771. PMID: 30298209; PMCID: PMC6290691. (2018)

Gutbier S, May P, Berthelot S, Krishna A, Trefzer T, Behbehani M, Efremova L, Delp J, Gstraunthaler G, Waldmann T, Leist M

 

➥Read more

Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity. ALTEX. 2018;35(3):306-352. doi: 10.14573/altex.1712081. Epub 2018 Feb 23. Erratum in: ALTEX. 2019;36(3):506. PMID: 29485663; PMCID: PMC6545888. (2018)

Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, Sachana M, Shafer TJ, Terron A, Monnet-Tschudi F, Viviani B, Waldmann T, Westerink RHS, Wilks MF, Witters H, Zurich MG, and Leist M

 

➥Read more

Stage-specific metabolic features of differentiating neurons: Implications for toxicant sensitivity. Toxicol Appl Pharmacol. 2018 Sep 1;354:64-80. doi: 10.1016/j.taap.2017.12.013. Epub 2017 Dec 24. Erratum in: Toxicol Appl Pharmacol. 2019 Jun 1;372:70. PMID: 29278688. (2018)

Delp J, Gutbier S, Cerff M, Zasada C, Niedenführ S, Zhao L, Smirnova L, Hartung T, Borlinghaus H, Schreiber F, Bergemann J, Gätgens J, Beyss M, Azzouzi S, Waldmann T, Kempa S, Nöh K, and Leist M

 

➥Read more

Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19. PMID: 29051992. (2017)

Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, Hartung T, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B, and Hengstler JG

 

➥Read more

Combination of multiple neural crest migration assays to identify environmental toxicants from a proof-of-concept chemical library. Arch Toxicol. 2017 Nov;91(11):3613-3632. doi: 10.1007/s00204-017-1977-y. Epub 2017 May 5. PMID: 28477266. (2017)

Nyffeler J, Dolde X, Krebs A, Pinto-Gil K, Pastor M, Behl M, Waldmann T, and Leist M

 

➥Read more

Stem Cell-Derived Immature Human Dorsal Root Ganglia Neurons to Identify Peripheral Neurotoxicants. Stem Cells Transl Med. 2016 Apr;5(4):476-87. doi: 10.5966/sctm.2015-0108. Epub 2016 Mar 1. PMID: 26933043; PMCID: PMC4798731. (2016)

Hoelting L, Klima S, Karreman C, Grinberg M, Meisig J, Henry M, Rotshteyn T, Rahnenführer J, Blüthgen N, Sachinidis A, Waldmann T, and Leist M

 

➥Read more

Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80. doi: 10.1007/s00204-015-1658-7. Epub 2015 Dec 26. PMID: 26705709; PMCID: PMC4710658. (2016)

Pallocca G, Grinberg M, Henry M, Frickey T, Hengstler JG, Waldmann T, Sachinidis A, Rahnenführer J, and Leist M

 

➥Read more

A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol. 2016 Nov;90(11):2725-2743. doi: 10.1007/s00204-015-1637-z. Epub 2015 Dec 8. PMID: 26647301; PMCID: PMC5065586. (2016)

Smirnova L, Harris G, Delp J, Valadares M, Pamies D, Hogberg HT, Waldmann T, Leist M, and Hartung T

 

➥Read more

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618. doi: 10.1007/s00204-015-1573-y. Epub 2015 Aug 14. PMID: 26272509; PMCID: PMC4551554. (2015)

Rempel E, Hoelting L, Waldmann T, Balmer NV, Schildknecht S, Grinberg M, Das Gaspar JA, Shinde V, Stöber R, Marchan R, van Thriel C, Liebing J, Meisig J, Blüthgen N, Sachinidis A, Rahnenführer J, Hengstler JG, and Leist M

 

➥Read more

Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70. doi: 10.1016/j.neuro.2015.07.008. Epub 2015 Jul 31. PMID: 26238599. (2015)

Dreser N, Zimmer B, Dietz C, Sügis E, Pallocca G, Nyffeler J, Meisig J, Blüthgen N, Berthold MR, Waldmann T, and Leist M

 

➥Read more

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation. J Vis Exp. 2015 Jun 17;(100):e52333. doi: 10.3791/52333. PMID: 26132533; PMCID: PMC4544843. (2015)

Shinde V, Klima S, Sureshkumar PS, Meganathan K, Jagtap S, Rempel E, Rahnenführer J, Hengstler JG, Waldmann T, Hescheler J, Leist M, and Sachinidis A

 

➥Read more

Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol. 2014 Dec;88(12):2261-87. doi: 10.1007/s00204-014-1400-x. Epub 2014 Nov 16. PMID: 25399406. (2014)

Grinberg M, Stöber RM, Edlund K, Rempel E, Godoy P, Reif R, Widera A, Madjar K, Schmidt-Heck W, Marchan R, Sachinidis A, Spitkovsky D, Hescheler J, Carmo H, Arbo MD, van de Water B, Wink S, Vinken M, Rogiers V, Escher S, Hardy B, Mitic D, Myatt G, Waldmann T, Mardinoglu A, Damm G, Seehofer D, Nüssler A, Weiss TS, Oberemm A, Lampen A, Schaap MM, Luijten M, van Steeg H, Thasler WE, Kleinjans JC, Stierum RH, Leist M, Rahnenführer J, and Hengstler JG

 

➥Read more

Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol. 2014 May;88(5):1109-26. doi: 10.1007/s00204-014-1231-9. Epub 2014 Apr 2. PMID: 24691702; PMCID: PMC3996367. (2014)

Zimmer B, Pallocca G, Dreser N, Foerster S, Waldmann T, Westerhout J, Julien S, Krause KH, van Thriel C, Hengstler JG, Sachinidis A, Bosgra S, and Leist M

 

➥Read more

From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68. doi: 10.1007/s00204-014-1279-6. Epub 2014 Jun 17. PMID: 24935251; PMCID: PMC4067541. (2014)

Balmer NV, Klima S, Rempel E, Ivanova VN, Kolde R, Weng MK, Meganathan K, Henry M, Sachinidis A, Berthold MR, Hengstler JG, Rahnenführer J, Waldmann T, and Leist M

 

➥Read more

faq ask icon

Cell Based Assay Development Service FAQs

What techniques do you use to measure endpoints?

We use a wide range of techniques to measure endpoints, e.g. FACS, Immunostaining, ELISA, Western blot and qPCR.

Based on which cell line types can you develop assays?

Our scientific experts can develop assays based on basic cell lines, customized cell lines or iPSC-derived cell types. For this, we use our in-house differentiation protocols with cardiomyocytes, hepatocyte-like cells or neurons for your analysis. Alternatively, you can provide us with your protocol so that after the technology transfer, our experts perform the work using this protocol internally at trenzyme.

Is it possible to order both, assay development and subsequent analysis of compounds?

Yes, our assay experts are delighted to develop an assay according to your needs prior to compound analysis.

See General FAQs
antje fuhrmann application & sales manager trenzyme
Antje Fuhrmann, PhD
Application & Sales Manager

We would be happy to provide you with support on your cell research project. Contact us and let us know your questions and requests to our cell services. Our scientific experts will reply shortly.

Get In Contact

With Our Scientific Experts

1 Step 1
keyboard_arrow_leftPrevious
Nextkeyboard_arrow_right
FormCraft - WordPress form builder